PT - JOURNAL ARTICLE AU - Lars Lau Raket AU - for the Alzheimer’s Disease Neuroimaging Initiative TI - Disease progression modeling in Alzheimer’s disease: insights from the shape of cognitive decline AID - 10.1101/2019.12.13.19014860 DP - 2019 Jan 01 TA - medRxiv PG - 2019.12.13.19014860 4099 - http://medrxiv.org/content/early/2019/12/15/2019.12.13.19014860.short 4100 - http://medrxiv.org/content/early/2019/12/15/2019.12.13.19014860.full AB - Background The characterizing symptom of Alzheimer disease (AD) is cognitive deterioration. While much recent work has focused on defining AD as a biological construct, most patients are still diagnosed, staged, and treated based on their cognitive symptoms. But the cognitive capability of a patient at any time throughout this deterioration will not directly reflect the disease state, but rather the effect of the cognitive decline on the patient’s predisease cognitive capability. Patients with high predisease cognitive capabilities tend to score better on cognitive tests relative to patients with low predisease cognitive capabilities at the same disease stage. Thus, a single assessment with a cognitive test is not adequate for determining the stage of an AD patient.Methods and Findings I developed a joint statistical model that explicitly modeled disease stage, baseline cognition, and the patients’ individual changes in cognitive ability as latent variables. The developed model takes the form of a nonlinear mixed-effects model. Maximum-likelihood estimation in this model induces a data-driven criterion for separating disease progression and baseline cognition. Applied to data from the Alzheimer’s Disease Neuroimaging Initiative, the model estimated a timeline of cognitive decline in AD that spans approximately 15 years from the earliest subjective cognitive deficits to severe AD dementia. It was demonstrated how direct modeling of latent factors that modify the observed data patterns provide a scaffold for understanding disease progression, biomarkers and treatment effects along the continuous time progression of disease.Conclusions The suggested framework enables direct interpretations of factors that modify cognitive decline. The results give new insights to the value of biomarkers for staging patients and suggest alternative explanations for previous findings related to accelerated cognitive decline among highly educated patients and patients on symptomatic treatments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by H. Lundbeck A/SAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified data from the Alzheimer's Disease Neuroimaging Study is available to the general scientific community. http://adni.loni.usc.edu/data-samples/access-data/